UBS Initiates Coverage On Ventyx Biosciences with Buy Rating, Announces Price Target of $20

Benzinga · 5d ago
UBS analyst Michael Yee initiates coverage on Ventyx Biosciences (NASDAQ:VTYX) with a Buy rating and announces Price Target of $20.